Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers | Zendy

Anja Rinke | Zendy; Thomas M. Gress | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers

Author(s) -

Anja Rinke,

Thomas M. Gress

Publication year - 2017

Publication title -

digestion

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.882

H-Index - 75

eISSN - 1421-9867

pISSN - 0012-2823

DOI - 10.1159/000454761

Subject(s) - medicine , neuroendocrine tumors , etoposide , oncology , carboplatin , chemotherapy , regimen , irinotecan , cisplatin , temozolomide , gemcitabine , malignancy , chemotherapy regimen , cancer , colorectal cancer

According to the latest WHO classification, neuroendocrine neoplasm (NEN) G3 of the gastrointestinal tract is defined by a proliferation index Ki67 above 20%. Gastrointestinal neuroendocrine carcinoma (NEC) is a rare and highly aggressive malignancy and despite responsiveness to chemotherapy, overall survival is poor. In the last 3-4 years, the heterogeneity of the NEN G3 group has become evident.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research